Ravitsemuslotionit

Ravitsemuslotionit are liquid nutritionally complete formulations designed to supply energy, protein, vitamins, minerals, and other nutrients in a single dose. They are typically used when oral intake of solid food is difficult or insufficient, such as in critically ill patients, individuals with dysphagia, or in long‑term care facilities. The term is derived from the Finnish words for nutrition (ravitsemus) and solution (lotion), and its use parallels the English “enteral nutrition solutions.”

The composition of a ravitsemuslotioni is regulated to meet specific caloric targets, usually ranging from 1.1 to 1.3 kilocalories per milliliter, and to provide a balance of macronutrients: carbohydrates (often maltodextrin or corn syrup solids), proteins (typically whey or soy protein), and lipids (medium‑chain triglycerides or blended emulsions). Micronutrients are added to satisfy recommended daily allowances, including trace elements such as zinc and selenium. Formulations may be tailored for patients with renal impairment, hepatic dysfunction, or glycemic control requirements, by adjusting protein type or carbohydrate content.

Clinically, ravitsemuslotionit are administered via feeding tubes or orally. Indications include malnutrition, postsurgical recovery, chemotherapy‑associated nausea, and chronic conditions such as Parkinson’s disease or amyotrophic lateral sclerosis where oral intake may be limited. Acceptance rates are generally high; however, gastrointestinal side effects such as bloating, diarrhea, or aspiration risk can occur, especially if administered too rapidly or in large volumes.

From a regulatory standpoint, ravitsemuslotionit are classified as dietary supplements or medical foods in Finland, depending on the intended use and labeling. Manufacturers must comply with the Finnish Food Authority’s guidelines for nutrient labeling, safety testing, and optional verification under the European Union’s medical food framework. While research supports their role in improving nutritional status and reducing hospital stay, ongoing studies aim to refine formulations for specific patient populations and to evaluate long‑term outcomes.